ArticleDiscover oncology2025
Efficacy and mechanisms of Angelica sinensis in treating endometrial cancer: an integrated study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAngelica-based formulas can improve quality of life in patients with endometrial cancer. However, the results remain controversial, and their mechanisms of action are unclear. In this study, we systematically explored the effects and mechanism of action of Angelica sinensis (AS) in endometrial cancer (EC) using network pharmacology and molecular docking.
methodsWe systematically searched PubMed, Embase, Cochrane Library, Web of Science, Chinese Science and Technology Journals (CQVIP), China Academic Journals (CNKI), Wanfang, and Chinese Biomedical Literature database (SinoMed). Nine randomized controlled trials were enrolled in the study. In network pharmacology, ingredients of Angelica sinensis were screened, endometrial cancer related genes were then identified and the 'Herb-Ingredient-Target-Disease' network constructed. Molecular docking was finally employed for in silico simulation matching between representative Angelica sinensis ingredients and their target genes.
resultsThe meta-analysis of this research provides evidence to support the efficacy of angelica-based formulas in the treatment of endometrial cancer. Network pharmacology demonstrated that EGFR, TP53, CTNNB1, CCND1, and HRAS are the core targets of endometrial cancer, and ferulic acid and caffeic acid are the major bioactive ingredients of Angelica sinensis. Molecular docking showed that ferulic acid and caffeic acid can closely bind core targets.
conclusionsOur study is the first to systematically apply bioinformatics methods-including meta-analysis, network pharmacology, and molecular docking-to explore the pharmacological and molecular mechanisms of Angelica sinensis in endometrial cancer treatment. Results of our study provide valuable scientific insights into the underlying mechanisms of Angelica sinensis in the treatment of endometrial cancer, serving as a crucial foundation for future research in this area.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.